PLX Protalix BioTherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: PLX

Price (delayed)

$1.46

Market cap

$106.51M

P/E Ratio

10.43

Dividend/share

N/A

EPS

$0.14

Enterprise value

$112.11M

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to ...

Highlights
PLX's net income has soared by 159% year-on-year and by 19% since the previous quarter
PLX's EPS has surged by 138% year-on-year and by 40% since the previous quarter
The gross profit has surged by 73% year-on-year but it has declined by 3.4% since the previous quarter
Protalix BioTherapeutics's quick ratio has decreased by 49% QoQ but it has increased by 34% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.protalix.com
Peers: FOLD NBIX TEVA PFE

Key stats

What are the main financial stats of PLX
Market
Shares outstanding
72.95M
Market cap
$106.51M
Enterprise value
$112.11M
Valuations
Price to earnings (P/E)
10.43
Price to book (P/B)
2.73
Price to sales (P/S)
1.66
EV/EBIT
7.61
EV/EBITDA
7.05
EV/Sales
1.76
Earnings
Revenue
$63.63M
EBIT
$14.74M
EBITDA
$15.89M
Free cash flow
-$8.64M
Per share
EPS
$0.14
Free cash flow per share
-$0.12
Book value per share
$0.53
Revenue per share
$0.88
TBVPS
$1.21
Balance sheet
Total assets
$87.57M
Total liabilities
$49.32M
Debt
$26.01M
Equity
$38.25M
Working capital
$29.26M
Liquidity
Debt to equity
0.68
Current ratio
1.67
Quick ratio
1.15
Net debt/EBITDA
0.35
Margins
EBITDA margin
25%
Gross margin
74%
Net margin
16.7%
Operating margin
21.3%
Efficiency
Return on assets
14.2%
Return on equity
62.8%
Return on invested capital
35.1%
Return on capital employed
33.3%
Return on sales
23.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PLX stock price

How has the Protalix BioTherapeutics stock price performed over time
Intraday
-3.31%
1 week
2.1%
1 month
-9.88%
1 year
32.73%
YTD
6.57%
QTD
-12.05%

Financial performance

How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$63.63M
Gross profit
$47.1M
Operating income
$13.58M
Net income
$10.62M
Gross margin
74%
Net margin
16.7%
Protalix BioTherapeutics's operating income has surged by 184% YoY and by 10% QoQ
The operating margin has soared by 162% YoY and by 16% from the previous quarter
PLX's net income has soared by 159% year-on-year and by 19% since the previous quarter
PLX's net margin has soared by 145% YoY and by 27% from the previous quarter

Growth

What is Protalix BioTherapeutics's growth rate over time

Valuation

What is Protalix BioTherapeutics stock price valuation
P/E
10.43
P/B
2.73
P/S
1.66
EV/EBIT
7.61
EV/EBITDA
7.05
EV/Sales
1.76
PLX's EPS has surged by 138% year-on-year and by 40% since the previous quarter
Protalix BioTherapeutics's revenue has increased by 34% YoY but it has decreased by 6% from the previous quarter
PLX's price to sales (P/S) is 18% lower than its last 4 quarters average of 2.1 but 8% higher than its 5-year quarterly average of 1.6

Efficiency

How efficient is Protalix BioTherapeutics business performance
PLX's return on sales has surged by 172% year-on-year and by 20% since the previous quarter
The ROA has soared by 152% YoY and by 7% from the previous quarter
Protalix BioTherapeutics's return on equity has shrunk by 69% QoQ
The return on invested capital has increased by 10% since the previous quarter

Dividends

What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLX.

Financial health

How did Protalix BioTherapeutics financials performed over time
PLX's total assets is 78% greater than its total liabilities
PLX's total assets has surged by 54% year-on-year
Protalix BioTherapeutics's quick ratio has decreased by 49% QoQ but it has increased by 34% YoY
PLX's debt is 32% less than its equity
The debt to equity has surged by 124% year-on-year
PLX's debt is down by 22% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.